Evidence map›Paper›PMID 42012954›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

CD28-driven ex vivo generation of stem-like memory CD8

Fumie Ihara, Yota Ohashi, Evey Y F Zheng, Saori Fukao, Rowena Rodrigo, Babak Noamani, Giselle M Boukhaled, Ben X Wang, Dong-Hoon Han, Xinyu Wei and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Fumie Ihara *Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Yota Ohashi *Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Evey Y F ZhengPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Saori FukaoPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Rowena RodrigoPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Babak NoamaniPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Giselle M BoukhaledPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Ben X WangPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Dong-Hoon HanPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Xinyu WeiPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Brian D BurtPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Kayoko SasoPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Yukiko MatsunagaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Dalam LyPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Yuki KagoyaDivision of Tumor Immunology, Institute for Advanced Medical Research, Keio University, Tokyo 160-8582, Japan.
Marcus O ButlerPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Tak W MakPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.ORCID 0000-0001-6766-861X
Samuel D SaibilPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Naoto HiranoPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.ORCID 0000-0001-9070-4754

Funding

Amgen Chair in Cancer Research N/ACanada Research Chairs (CRC) N/ACanadian Institutes of Health Research (CIHR) DV1-197666Longo Family Cancer Foundation N/AOntario Institute for Cancer Research (OICR) IA-039Princess Margaret Cancer Foundation (PMCF) N/A
6 · The paper itself

Abstract

Adoptive T cell therapies typically rely on ex vivo CD3/CD28 stimulation, which promotes effector differentiation and limits the persistence of transferred cells. Stem cell-like memory T cells (Tscm), with their capacity for self-renewal and multipotency, represent an ideal therapeutic subset but remain difficult to generate at scale. Here, we present a CD3-independent strategy using artificial antigen-presenting cells expressing a membrane-bound CD28 superagonist (αCD28-aAPCs) to expand CD8

Indexed as

CD28 AntigensCD3 ComplexCD8-Positive T-LymphocytesImmunologic MemoryMemory T CellsReceptors, Antigen, T-CellAnimalsAntigen-Presenting CellsCell DifferentiationHepatocyte Nuclear Factor 1-alphaInterferon Regulatory Factor-4Interferon Regulatory FactorsLymphocyte ActivationMiceMice, Inbred C57BLPositive Regulatory Domain I-Binding Factor 1CD28 AntigensCD3 ComplexHepatocyte Nuclear Factor 1-alphaHnf1a protein, mouseInterferon Regulatory Factor-4Interferon Regulatory FactorsPositive Regulatory Domain I-Binding Factor 1Receptors, Antigen, T-Celladoptive T cell therapyartificial antigen-presenting cellsCD28 signalingCD3-independent activationstem cell–like memory T cells

Identifiers

PMID42012954
PMCPMC13123868

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.